GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Designer Probiotics for the treatment of intestinal infection and inflammation

$744,110
Cammie Lesser · Massachusetts General Hospital · R01 · FY2017 · DK

Applications of a robust, vector-free intracellular delivery platform for immune cells

$743,988
Scott McNabb Loughhead · Sqz Biotechnologies Company, Inc. · R44 · FY2017 · GM

AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

$742,887
Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2024 · CA

AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

$742,887
Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R44 · FY2025 · CA

Evaluation of Novel Radiation Modifiers

$742,307
Deborah Citrin · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Augmented Transgenic TCR-mediated tumor therapy

$742,305
Aude Chapuis · University Of Washington · P01 · FY2025 · CA

Mechanism of estrogen independent proliferation in ER+ breast cancer cells

$742,035
Andrea Hope Bild · Beckman Research Institute/City Of Hope · U01 · FY2022 · CA

Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC

$741,917
Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer

$741,840
David P Carbone · Ohio State University · R01 · FY2025 · CA

Imaging tumor and T cell responses to metabolic and immune modulation therapy

$741,049
Taha Merghoub · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Administrative Core

$741,000
Jun Yan · University Of Louisville · P20 · FY2020 · GM

PROJECT 2: Development and Refinement of Predictive Models for Designing Immunotherapy Combination Treatments

$740,955
Vesteinn Thorsson · Institute For Systems Biology · U54 · FY2024 · CA

Molecular, Cellular and Genetic Analyses of Malignancies Associated with NF1

$740,152
Karlyne M Reilly · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

PROJECT 2: Development and Refinement of Predictive Models for Designing Immunotherapy Combination Treatments

$739,484
Vesteinn Thorsson · Institute For Systems Biology · U54 · FY2025 · CA

Project 1 - Clinical Trial

$738,729
Andrew R Haas · University Of Pennsylvania · P01 · FY2019 · CA

Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors

$737,882
Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2018 · CA

Administrative Core

$737,703
Jun Yan · University Of Louisville · P20 · FY2021 · GM

A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events

$737,672
Adam Mor · Columbia University Health Sciences · R01 · FY2023 · AI

A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events

$737,672
Adam Mor · Columbia University Health Sciences · R01 · FY2024 · AI

Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade

$737,605
Roger D. Kamm · Massachusetts Institute Of Technology · U01 · FY2018 · CA

Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors

$737,531
Michael Karin · University Of California, San Diego · U01 · FY2018 · AA

Identifying new immunotherapeutic targets for endocrine autoimmunity.

$737,346
Maureen A Su · University Of California Los Angeles · U19 · FY2024 · AI

Identifying new immunotherapeutic targets for endocrine autoimmunity.

$737,346
Maureen A Su · University Of California Los Angeles · U19 · FY2025 · AI

Variation in tumor-associated immune profiles and colorectal cancer outcomes

$736,864
Stephanie L. Schmit · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · CA

Evolution of gliomas during treatment and resistance

$736,601
Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2021 · CA